Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients with MSI/dMMR Stage III Colon Cancer
The ACCENT database analysis supports flouropyrimidine plus oxaliplatin as standard-of-care adjuvant treatment for patients with MSI/dMMR stage III colon cancer